Salidroside attenuates endothelial cellular senescence via decreasing the expression of inflammatory cytokines and increasing the expression of SIRT3

Mech Ageing Dev. 2018 Oct:175:1-6. doi: 10.1016/j.mad.2017.12.005. Epub 2017 Dec 28.

Abstract

Objective: Endothelial cellular senescence is an important contributor to the endothelial dysfunction and atherosclerosis. Our previous studies suggested that salidroside (SAL) can alleviate atherosclerosis and protect endothelial cells against oxidative stress induced damage. However, the effect and mechanism of SAL on endothelial cellular senescence is still unclear. Here, we investigated the underlying mechanisms of SAL on preventing endothelial cellular premature senescence.

Methods and results: We established a hyperhomocysteinemia (HHcy)mouse model via high methionine diet (HMD) to explore the protective effect of SAL. According to our results, the HMD elevated the concentration of serum homocysteine. HHcy induced the collagen deposition and the up-regulation of senescence markers, i.e. p16INK4A and p21CIP1, in intima-medial of aorta. In addition, SAL also inhibited the expression of CD68 and intercellular adhesion molecule 1 (ICAM1) in aorta. In senescent human umbilical vein endothelial cells (HUVECs) induced by H2O2, SAL treatment alleviated the expression of p16INK4A and p21CIP1 and reduced the activity of senescence-associated (SA)-β-gal.

Conclusion: our data suggested that SAL decreased the expression of inflammatory cytokines and up-regulated the expression of SIRT3, which might be the underlying mechanism of SAL on preventing endothelial cells from premature senescence.

Keywords: Endothelial cellular senescence; Inflammatory cytokines; SIRT3; Salidroside.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Aorta / drug effects*
  • Aorta / enzymology
  • Aorta / pathology
  • Cells, Cultured
  • Cellular Senescence / drug effects*
  • Collagen / metabolism
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • Cyclin-Dependent Kinase Inhibitor p21 / metabolism
  • Cytokines / metabolism*
  • Disease Models, Animal
  • Glucosides / pharmacology*
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / enzymology
  • Human Umbilical Vein Endothelial Cells / pathology
  • Humans
  • Hyperhomocysteinemia / drug therapy*
  • Hyperhomocysteinemia / enzymology
  • Hyperhomocysteinemia / pathology
  • Inflammation Mediators / metabolism*
  • Male
  • Mice, Inbred BALB C
  • Phenols / pharmacology*
  • Sirtuin 3 / metabolism*
  • Up-Regulation
  • Vascular Remodeling / drug effects
  • beta-Galactosidase / metabolism

Substances

  • Anti-Inflammatory Agents
  • CDKN2A protein, human
  • Cdkn1a protein, mouse
  • Cdkn2a protein, mouse
  • Cyclin-Dependent Kinase Inhibitor p16
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cytokines
  • Glucosides
  • Inflammation Mediators
  • Phenols
  • Sirt3 protein, mouse
  • Collagen
  • beta-Galactosidase
  • SIRT3 protein, human
  • Sirtuin 3
  • rhodioloside